| Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy (NCT06049134) | M.D. Anderson Cancer Center | 2023-10-06 |
| Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection (NCT05879159) | M.D. Anderson Cancer Center | 2023-10-05 |
| An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma (NCT05929716) | M.D. Anderson Cancer Center | 2023-09-30 |
| Evaluating Mechanical Properties of Post-Mastectomy Skin Flaps to Estimate Reconstruction Risks, the EMPOWER Study (NCT06584396) | M.D. Anderson Cancer Center | 2023-09-20 |
| Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer (NCT05406232) | M.D. Anderson Cancer Center | 2023-09-15 |
| Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia (NCT06085638) | M.D. Anderson Cancer Center | 2023-09-14 |
| A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma (NCT05621668) | M.D. Anderson Cancer Center | 2023-09-08 |
| A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology (NCT05977998) | M.D. Anderson Cancer Center | 2023-09-08 |
| Spanish Decision Tool for Ovarian Cancer Maintenance Therapy (NCT06036810) | M.D. Anderson Cancer Center | 2023-08-31 |
| Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer (NCT05761951) | M.D. Anderson Cancer Center | 2023-08-29 |
| Cultural Tailoring and Pilot Testing of an Inpatient Yoga Therapy Program for Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation in India, Tanzania, and the United States (NCT05681026) | M.D. Anderson Cancer Center | 2023-08-28 |
| Data Collection Protocol for Patients With Von Hippel Lindau Disease (NCT05955014) | M.D. Anderson Cancer Center | 2023-08-24 |
| 18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer (NCT06549413) | M.D. Anderson Cancer Center | 2023-08-23 |
| Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection (NCT05873699) | M.D. Anderson Cancer Center | 2023-08-18 |
| A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. (NCT05704634) | M.D. Anderson Cancer Center | 2023-08-18 |
| Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients (NCT05776979) | M.D. Anderson Cancer Center | 2023-08-17 |
| Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion (NCT06184321) | M.D. Anderson Cancer Center | 2023-08-17 |
| A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors (NCT06006273) | M.D. Anderson Cancer Center | 2023-08-16 |
| Peripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study (NCT06004882) | M.D. Anderson Cancer Center | 2023-08-10 |
| A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma (NCT06006286) | M.D. Anderson Cancer Center | 2023-08-08 |
| Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification (NCT05510427) | M.D. Anderson Cancer Center | 2023-08-07 |
| Safety, Tolerability, and Efficacy of Enteral Nutrition Versus Standard of Care Nutrition in Hematopoietic Stem Cell Transplant Patients: A Pilot Study (NCT06004063) | M.D. Anderson Cancer Center | 2023-08-04 |
| Prophylactic Lymphovenous Bypass Procedure Following Inguinal Lymphadenectomy or Pelvic Lymphadenectomy: A Prospective Observational Study (NCT05992909) | M.D. Anderson Cancer Center | 2023-08-02 |
| An Evaluation of the Implementation of the Care and Monitoring at Home Program- A New Paradigm for Acute Care Management of Cancer Patients (NCT05904899) | M.D. Anderson Cancer Center | 2023-08-01 |
| A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma (NCT05929612) | M.D. Anderson Cancer Center | 2023-07-28 |
| Health Benefits of Writing Therapy Among Asian American Cancer Survivors (NCT06367959) | M.D. Anderson Cancer Center | 2023-07-27 |
| Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers (NCT05884320) | M.D. Anderson Cancer Center | 2023-07-27 |
| Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer (NCT05836870) | M.D. Anderson Cancer Center | 2023-07-18 |
| Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer (NCT05819892) | M.D. Anderson Cancer Center | 2023-07-17 |
| Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia (NCT05645718) | M.D. Anderson Cancer Center | 2023-07-14 |
| Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer (NCT05636111) | M.D. Anderson Cancer Center | 2023-07-12 |
| A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (NCT05961696) | M.D. Anderson Cancer Center | 2023-07-05 |
| 3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial (NCT05674396) | M.D. Anderson Cancer Center | 2023-06-30 |
| Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC (NCT05663710) | M.D. Anderson Cancer Center | 2023-06-30 |
| A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors (NCT05672459) | M.D. Anderson Cancer Center | 2023-06-21 |
| Reminder Messages for Lung Cancer Screening (NCT05952778) | M.D. Anderson Cancer Center | 2023-06-20 |
| A Pilot Clinical Trial to Determine the Feasibility of Administering an Electronic Tool to Assess Postoperative pAin, Nausea, and Vomiting in English or Spanish-Speaking Pediatric Patients With Neoplastic Conditions. (NCT05933252) | M.D. Anderson Cancer Center | 2023-06-19 |
| Precision Optical Guidance for Oral Biopsy (NCT05554133) | M.D. Anderson Cancer Center | 2023-06-15 |
| A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma (NCT05335941) | M.D. Anderson Cancer Center | 2023-06-13 |
| A Virtually Delivered Exercise Intervention To Mitigate Cognitive Deficits From Radiotherapy In AYAs With Brain Tumors (NCT05554159) | M.D. Anderson Cancer Center | 2023-06-05 |
| Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) (NCT05700721) | M.D. Anderson Cancer Center | 2023-06-02 |
| Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). (NCT05681039) | M.D. Anderson Cancer Center | 2023-06-02 |
| Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Efficacy Testing (NCT06785441) | M.D. Anderson Cancer Center | 2023-05-25 |
| A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) (NCT05675579) | M.D. Anderson Cancer Center | 2023-05-23 |
| A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (NCT05683171) | M.D. Anderson Cancer Center | 2023-05-19 |
| Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) (NCT05900648) | M.D. Anderson Cancer Center | 2023-05-17 |
| HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic Leukemia (NCT05879133) | M.D. Anderson Cancer Center | 2023-05-17 |
| A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) (NCT05673928) | M.D. Anderson Cancer Center | 2023-05-16 |
| Phase II Cohort of Spinal Stereotactic Radiotherapy in Patients Using a MR LINAC (NCT05709782) | M.D. Anderson Cancer Center | 2023-05-09 |
| Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies (NCT05039632) | M.D. Anderson Cancer Center | 2023-05-08 |
| Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients (NCT05634525) | M.D. Anderson Cancer Center | 2023-05-03 |
| A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL (NCT05615636) | M.D. Anderson Cancer Center | 2023-04-28 |
| Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM (NCT04991870) | M.D. Anderson Cancer Center | 2023-04-28 |
| A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations (NCT05848843) | M.D. Anderson Cancer Center | 2023-04-25 |
| Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study (NCT05019703) | M.D. Anderson Cancer Center | 2023-04-25 |
| Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas (NCT05804227) | M.D. Anderson Cancer Center | 2023-04-20 |
| New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study (NCT04481204) | M.D. Anderson Cancer Center | 2023-04-18 |
| A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas (NCT05773040) | M.D. Anderson Cancer Center | 2023-04-14 |
| Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention (NCT05677048) | M.D. Anderson Cancer Center | 2023-04-14 |
| Assessment of Patient Experience and Needs for Patients Undergoing Invasive Inguinal Lymph Node Procedures for Penile Cancer (NCT05842031) | M.D. Anderson Cancer Center | 2023-04-14 |
| Developing a Culturally Relevant Supportive Care Program for Black Patients Dealing With Advanced Cancer (NCT05763797) | M.D. Anderson Cancer Center | 2023-04-13 |
| Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL (NCT05464836) | M.D. Anderson Cancer Center | 2023-04-06 |
| Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation (NCT05774678) | M.D. Anderson Cancer Center | 2023-04-05 |
| Metformin and Nightly Fasting in Women With Early Breast Cancer (NCT05023967) | M.D. Anderson Cancer Center | 2023-04-04 |
| Active Living After Cancer: Implementation Within Be Well Acres Homes (NCT06907706) | M.D. Anderson Cancer Center | 2023-04-03 |
| Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance (NCT05840484) | M.D. Anderson Cancer Center | 2023-03-29 |
| Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma (NCT05703854) | M.D. Anderson Cancer Center | 2023-03-29 |
| A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma (NCT05634577) | M.D. Anderson Cancer Center | 2023-03-23 |
| The Attitudes and Beliefs of Hispanic/Latino Individuals Toward Prescription Opioids and Non-Medical Opioid Use (NCT05529082) | M.D. Anderson Cancer Center | 2023-03-23 |
| A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome (NCT05411718) | M.D. Anderson Cancer Center | 2023-03-21 |
| Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy (NCT05717400) | M.D. Anderson Cancer Center | 2023-03-17 |
| TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning (NCT05743842) | M.D. Anderson Cancer Center | 2023-03-14 |
| Implementation of Digital Vital Sign Monitoring to Decrease Sleep Interruption and Enhance Recovery in Phase II of the PROmoting Sleep, Patient Engagement and Recovery (PROSPER) Project (NCT05456360) | M.D. Anderson Cancer Center | 2023-03-01 |
| Vapocoolant Analgesia for Breast Lymphoscintigraphy (NCT05744557) | M.D. Anderson Cancer Center | 2023-03-01 |
| A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors (NCT05120960) | M.D. Anderson Cancer Center | 2023-02-27 |
| A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer (NCT05226663) | M.D. Anderson Cancer Center | 2023-02-27 |
| A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy (NCT05039736) | M.D. Anderson Cancer Center | 2023-02-24 |
| Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases (NCT05704647) | M.D. Anderson Cancer Center | 2023-02-23 |
| Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas (NCT05676450) | M.D. Anderson Cancer Center | 2023-02-23 |
| Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma (NCT05394337) | M.D. Anderson Cancer Center | 2023-02-23 |
| Stereotactic Liver Ablation Assisted With Intra-Arterial CT Hepatic Arteriography and Ablation Confirmation Software Assessment (STEREOLAB) (NCT05361551) | M.D. Anderson Cancer Center | 2023-02-21 |
| A Randomized Trial Comparing a Ventilatory Strategy To Prevent Atelectasis Versus a Lateral Decubitus Strategy During Robotic Bronchoscopy (VESPA vs. LADS Trial) (NCT05714033) | M.D. Anderson Cancer Center | 2023-02-10 |
| Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer (NCT05633979) | M.D. Anderson Cancer Center | 2023-02-09 |
| Perceptions on Expected Outcomes of Immunotherapy in Advanced Cancer Patients With Poor Performance Status (NCT05634551) | M.D. Anderson Cancer Center | 2023-02-09 |
| Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. (NCT05501054) | M.D. Anderson Cancer Center | 2023-02-09 |
| The Use of Cannabis (Marijuana) and Cannabidiol (CBD) Among Cancer Patients: A Pilot Study (NCT05836857) | M.D. Anderson Cancer Center | 2023-01-30 |
| Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients (NCT05529069) | M.D. Anderson Cancer Center | 2023-01-25 |
| REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) (NCT05632809) | M.D. Anderson Cancer Center | 2023-01-10 |
| Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients (NCT05101213) | M.D. Anderson Cancer Center | 2023-01-06 |
| Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma (NCT05065047) | M.D. Anderson Cancer Center | 2023-01-05 |
| Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) (NCT05536349) | M.D. Anderson Cancer Center | 2022-12-20 |
| Sexual Dysfunction in Palliative Care Patients: An Assessment of Patient's Perspective (NCT05837117) | M.D. Anderson Cancer Center | 2022-12-15 |
| Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors (NCT05431582) | M.D. Anderson Cancer Center | 2022-12-14 |
| Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) (NCT05475171) | M.D. Anderson Cancer Center | 2022-12-13 |
| The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts (NCT05667532) | M.D. Anderson Cancer Center | 2022-12-05 |
| Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma (NCT05091372) | M.D. Anderson Cancer Center | 2022-12-01 |
| Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics (NCT05694559) | M.D. Anderson Cancer Center | 2022-11-23 |
| Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer (NCT05474846) | M.D. Anderson Cancer Center | 2022-11-21 |
| A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma (NCT05495464) | M.D. Anderson Cancer Center | 2022-11-18 |
| Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics. (NCT05649072) | M.D. Anderson Cancer Center | 2022-11-18 |